GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » scPharmaceuticals Inc (STU:2SX) » Definitions » ROE % Adjusted to Book Value

scPharmaceuticals (STU:2SX) ROE % Adjusted to Book Value : -23.99% (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is scPharmaceuticals ROE % Adjusted to Book Value?

scPharmaceuticals's ROE % for the quarter that ended in Jun. 2024 was -407.18%. scPharmaceuticals's PB Ratio for the quarter that ended in Jun. 2024 was 16.97. scPharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was -23.99%.


scPharmaceuticals ROE % Adjusted to Book Value Historical Data

The historical data trend for scPharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

scPharmaceuticals ROE % Adjusted to Book Value Chart

scPharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only - -25.71 -17.59 -18.19 -16.18

scPharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.91 -21.80 -20.85 -25.07 -23.99

Competitive Comparison of scPharmaceuticals's ROE % Adjusted to Book Value

For the Biotechnology subindustry, scPharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


scPharmaceuticals's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, scPharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where scPharmaceuticals's ROE % Adjusted to Book Value falls into.



scPharmaceuticals ROE % Adjusted to Book Value Calculation

scPharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-98.06% / 6.06
=-16.18%

scPharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-407.18% / 16.97
=-23.99%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


scPharmaceuticals ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of scPharmaceuticals's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


scPharmaceuticals Business Description

Traded in Other Exchanges
Address
25 Mall Road, Suite 203, Burlington, MA, USA, 01803
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.

scPharmaceuticals Headlines

No Headlines